Clinical Trial Update: Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial assesses avelumab in combination with binimetinib, sacituzumab govitecan, or liposomal doxorubicin in patients with stage IV or unresectable,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Avelumab (avelumab)
• Binimetinib (binimetinib)
• Doxil (liposomal doxorubicin)
• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: Laura Huppert, MD, BA | Conditions: Stage III Breast Cancer, Stage IIIA Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING